Sandeep Dhaliwal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sandeep Dhaliwal has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Aftab Ahmed Ansari
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA
1 shared publication - Christopher L. Bowlus
Division of Gastroenterology and Hepatology University of California Davis School of Medicine Sacramento California USA
1 shared publication - Guo-Xiang Yang
Division of Rheumatology, Allergy and Clinical Immunology, University of California at Davis, Davis, CA, United States
1 shared publication - Ian R. Mackay
Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, Australia
1 shared publication - Jinjun Wang
Division of Rheumatology, Allergy and Clinical Immunology, University of California, Davis, CA, USA
1 shared publication - Jun Zhang
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
1 shared publication
Latest Publications
- Open Access
- 12 July 2014
- Published by Wolters Kluwer Health in Hepatology
- Vol. 60 (5) , 1708-1716
Ongoing activation of autoantigen-specific B cells in primary biliary cirrhosis
The serologic hallmark of primary biliary cirrhosis (PBC), the antimitochondrial response to the E2 component of the pyruvate dehydrogenase complex (PDC-E2), has unique features, including continuous high titers of immunoglobulin M (IgM) and IgG reactivity throughout all stages of disease, capable not only of target enzyme inhibition, but also crossreactive with chemical xenobiotics that share molecular homology with the inner lipoyl domain of PDC-E2; such chemicals have been proposed as potential etiological agents. We used flow cytometry and enzyme-linked immunospot assay (ELISPOT) to examine B-cell subsets in 59 subjects, including 28 with PBC, 13 with primary sclerosing cholangitis (PSC), and 18 healthy controls. Strikingly, in PBC, although there were no significant differences in B-cell phenotype subpopulations, 10% of the total IgG and IgA plasmablast population and 23% of the IgM plasmablast population were uniquely reactive with PDC-E2, detected in the CXCR7+CCR10low plasmablast population. In contrast, plasmablast reactivity to a control antigen, tetanus toxoid, was minimal and similar in all groups. Additionally, we isolated plasmablast-derived polyclonal antibodies and compared reactivity with plasma-derived antibodies and noted a distinct noncirculating tissue source of xenobiotic crossreacting antibodies. The high levels of autoantigen specific peripheral plasmablasts indicate recent activation of naive or memory B cells and a continuous and robust activation. The presence of CXCR7+CCR10low PDC-E2-specific ASCs suggests a mechanistic basis for the migration of circulating antigen specific plasmablasts to the mucosal epithelial ligands CXCL12 and CCL28. Conclusion : Our findings suggest a sustained rigorous B-cell response in PBC, likely activated and perpetuated by cognate autoantigen. (Hepatology 2014;60:1708–1716)
- 12 July 2014
- Published by Wolters Kluwer Health in Hepatology
- Vol. 60 (5) , 1708-1716
Open AccessOngoing activation of autoantigen-specific B cells in primary biliary cirrhosis
The serologic hallmark of primary biliary cirrhosis (PBC), the antimitochondrial response to the E2 component of the pyruvate dehydrogenase complex (PDC-E2), has unique features, including continuous high titers of immunoglobulin M (IgM) and IgG reactivity throughout all stages of disease, capable not only of target enzyme inhibition, but also crossreactive with chemical xenobiotics that share molecular homology with the inner lipoyl domain of PDC-E2; such chemicals have been proposed as potential etiological agents. We used flow cytometry and enzyme-linked immunospot assay (ELISPOT) to examine B-cell subsets in 59 subjects, including 28 with PBC, 13 with primary sclerosing cholangitis (PSC), and 18 healthy controls. Strikingly, in PBC, although there were no significant differences in B-cell phenotype subpopulations, 10% of the total IgG and IgA plasmablast population and 23% of the IgM plasmablast population were uniquely reactive with PDC-E2, detected in the CXCR7+CCR10low plasmablast population. In contrast, plasmablast reactivity to a control antigen, tetanus toxoid, was minimal and similar in all groups. Additionally, we isolated plasmablast-derived polyclonal antibodies and compared reactivity with plasma-derived antibodies and noted a distinct noncirculating tissue source of xenobiotic crossreacting antibodies. The high levels of autoantigen specific peripheral plasmablasts indicate recent activation of naive or memory B cells and a continuous and robust activation. The presence of CXCR7+CCR10low PDC-E2-specific ASCs suggests a mechanistic basis for the migration of circulating antigen specific plasmablasts to the mucosal epithelial ligands CXCL12 and CCL28. Conclusion : Our findings suggest a sustained rigorous B-cell response in PBC, likely activated and perpetuated by cognate autoantigen. (Hepatology 2014;60:1708–1716)